- Conditions
- Heart Failure, Acute Kidney Injury
- Interventions
- Dapagliflozin 10mg Tab, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 612
matching trials from the live ClinicalTrials.gov search.
- Conditions
- IGT - Impaired Glucose Tolerance, T2D
- Interventions
- Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
- Interventions
- Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
- Drug · Other · Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetes Mellitus, Cancer
- Interventions
- Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pancreatic Neoplasms, Bile Duct Neoplasms
- Interventions
- Oxaliplatin, Capecitabine, Sorafenib
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Orforglipron, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 929 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 74
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- PreDiabetes, Overweight, Impaired Glucose Tolerance
- Interventions
- Timing of OGTT, Timing of Standardized Meal
- Diagnostic Test · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 23 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity
- Interventions
- Exendin 9-39 and Sitagliptin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes
- Interventions
- vitamin D3, cholecalciferol, Inactive comparator
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 19 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Postoperative Pain Control, Opioid Consumption
- Interventions
- Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- hCG
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 37 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Critical Illness, Acute Respiratory Failure
- Interventions
- Olimel (5.7%E / N9E)
- Drug
- Lead sponsor
- Clinical Evaluation Research Unit at Kingston General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Boulder, Colorado • St Louis, Missouri • Cleveland, Ohio + 3 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin, Oral combined hormonal contraceptives
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years to 49 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
- Interventions
- Placebo, Sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • San Antonio, Texas
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
- Interventions
- Weight loss
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Glucose Tolerance, HRV
- Interventions
- Feet heating, Calf heating
- Procedure
- Lead sponsor
- San Diego State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Major Depressive Disorder
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gestational Diabetes, Pregnancy Related
- Interventions
- Observational
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Honolulu, Hawaii • Chicago, Illinois + 5 more
- Conditions
- Ketosis, Glucose Metabolism
- Interventions
- Ketone ester, Glucose
- Dietary Supplement
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Natick, Massachusetts
- Conditions
- Gestational Diabetes
- Interventions
- 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
- Diagnostic Test
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Chapel Hill, North Carolina